Ore Huiying / Bloomberg / Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales ...

Eli Lilly (LLY) stock is higher Thursday after the pharmaceutical company beat profit expectations and matched revenue forecasts for its fourth quarter and issued a better-than-expected outlook ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

Eli Lilly’s momentum stems from blockbuster GLP-1 therapies (Mounjaro, Zepbound), fuelling revenue growth, long-term margin expansion, and an ethos driving America’s health focus across ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s leader can become tomorrow’s laggard without continuous development ...

Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and commercialization of OliX’s OLX75016, a Phase 1 candidate ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow morning. Here’s what to expect. Eli Lilly missed analysts’ revenue expectations by 6% last quarter ...

The film follows a group of teenagers who plan the perfect heist by breaking into their middle school to alter their failing ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...

Eli Lilly said it expects to release data from a late-stage trial on its next-generation weight loss drug retatrutide in 2025, a few months earlier than expected. The company expects to provide ...

Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...